Psychedelic Therapy NQ

Psychedelic Therapy NQ The intention to bring our skills of integration support and therapy to the wider community. Integration Therapy of altered state or state change experiences.

The intention of this is to start to bring our skills of integration support and therapy to the wider community. Studies have shown integration is an integral part of the Altered State experience, such as Holotropic/Psychedelic Breath Work & Psychedelic Medicine Journeys. Utilising emotional embodiment of Somatic experiencing (the bottom up approach). The older common model of top down or the cognitive approach can re-create our same old stories or protections. With this new and proven therapy we can identify and shift mind sets and expand perspectives to accept a wider view. Without integration we can be left confused and, in some instances, overwhelmed, which can lead to increased mental health challenges. The psychedelic/altered state session is a small part of a much larger healing journey. As some people are experimenting and while some medications are still illegal, we understand many people are exploring these altered states perhaps by themselves. We would like to offer support in the way of integration. When we are able to embody our experience of altered states, we start to see the ripple effect of change in our lives. If you or you know of someone struggling with an experience they may have had with medicine or any altered state please let them know there are ways to support this process. It doesn’t matter if it was last night or 30 years ago, the amazing part of this work is that it can be embodied at any time. Graduate CPAT from MMI. Certificate of Psychedelic Assisted Therapies Mind Medicine Institute.

12/11/2025

If you’ve ever felt called to contribute to psychedelic culture, harm reduction, or education, now’s the time.

We’re excited to invite you to our upcoming APS Volunteer Intake Session, hosted by APS Vice President Antanika Hoberg.

This one-hour session will take you through the APS Volunteer Hub - our dedicated online space for volunteers to learn, connect, and contribute to the Society’s work.

During the session, we’ll explore:
- How to use the APS Hub and find your way around.
- The New Volunteer Induction Course, which introduces you to APS and our values
- Resources, templates, and upcoming events
- How to match your interests and skills with volunteer opportunities

You’ll also have a chance to meet others from the APS team, ask questions, and connect with community members around Australia.

For information on this event- please see the link in the comments section!

09/11/2025

AMAPP is excited to support the Psychedelic Lived Experiences Summit; a free, 3-day virtual gathering centering the real stories of people involved in psychedelic-assisted therapies.

Across three days, you’ll hear from 50+ lived-experience speakers, therapists, and researchers sharing honest, nuanced stories that move beyond hype and into the heart of what truly helps, harms, and heals.

This aligns with our AMAPP mission of peer support, advocacy, and co creating ecosystems of trust in PAT.

If it resonates with you or your community, we’d love you to join us.

Let’s keep shaping a field that’s ethical, human, and guided by lived wisdom.

🗓 Nov 21–23, 2025
🌐 Free Registration: https://psychedeliclivedexperiences.com/summit

.lived.exp

06/11/2025

The Department of Veterans’ Affairs has recently approved the funding of M**A for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD), where these are used in combination with intensive psychotherapy.

Further provider information and funding application forms are available at the links below:

Application form: https://buff.ly/jFYTxfi

Information for veterans: https://buff.ly/9enSFuZ

Information for providers: https://buff.ly/xUn88Kj

Australian Government Department of Veterans' Affairs

28/10/2025

The latest newsletter will contain Info, events, an exclusive EGA discount code, psychedelic articles and more. Plus an opportunity to get YOUR psychedelic story published on the APS website!
Be the first to access all this plus more by signing up to the APS newsletter today! Find the link in the comments below.

25/10/2025

Research into psychedelics help to support a safer and more informed space for the community. If you are able to help participate in this particular research please reach out to swil2882@uni.sydney.edu.au

15/10/2025

How Will You Change? Your Beliefs Shape Your Biology.

Video at YouTube.com/watch?v=e71exrhEBQc

14/10/2025

“Australia’s first psychedelic trial for treatment-resistant depression has uncovered potential markers that could predict which patients will respond to the emerging therapy.

The pilot study tracked eight patients over 12 weeks of treatment, which involves two sessions on psilocybin, the active ingredient in magic mushrooms, alongside talk therapy to prepare and then process the experience.”

Read the full article for subscribers of Herald Sun: https://buff.ly/GaSs6XR

Read the full PDF article: https://buff.ly/5cQ4nly

10/10/2025

Psilocybe species and Amanita muscaria are sometimes misrepresented or mistaken as similar “magic mushrooms.” In reality, they are unrelated, act on different receptor systems, and produce very different experiences. Confusion between them has led to adverse reactions and toxic outcomes.

🍄‍🟫Psilocybe species (for example cubensis, subaeruginosa)
• Contain psilocybin, which converts in the body to psilocin
• Psilocin acts on serotonin (5-HT2A) receptors
• Classified as serotonergic psychedelics
• Experiences may involve altered perception, visual effects, emotional release, or introspection
• Physiological toxicity is low, but experiences can be psychologically intense or distressing, particularly in unsupported settings
•Understanding of wood lovers paralysis risk when consuming wood loving psilocybe mushrooms is recommended
• Psilocybin is a controlled substance in Australia and is only legally accessible through approved clinical or research use

🍄 Amanita muscaria (Fly agaric)
• Contains ibotenic acid and muscimol, which act on GABA-A receptors, not serotonin
• Classified as a GABAergic deliriant or sedative, not a serotonergic psychedelic
• Associated with sedative, dreamlike, or dissociative states, which can include confusion, loss of coordination, and nausea
• Ibotenic acid is neurotoxic and may cause vomiting, delirium, and physical discomfort
• Drying or heating causes partial decarboxylation, converting some ibotenic acid into muscimol. This reduces but does not necessarily remove toxicity. If working with Amanita Muscaria it is important to refer to reputable sources for information on preparation to avoid toxicity
• Even dried Amanita muscaria remains unpredictable, and potency varies greatly between specimens

🛡️Harm Reduction Summary:
• These mushrooms act on different receptor systems and should never be considered interchangeable
• Decarboxylation does not always make Amanita safe
• Psilocybe species have low physiological toxicity but may cause emotional intensity or confusion
• Amanita muscaria has higher physiological risk and a greater likelihood of nausea, toxicity, or delirium
• Misidentification between species can lead to serious poisoning
• Combining either with alcohol, sedatives, or other psychoactive substances increases risk
•If you are planning to use Amanita Muscaria it is important that you access reliable sources on preparation to avoid toxicity

🏷️Legal Context in Australia:
• Psilocybin is legally accessible only through regulated medical or research pathways
• Muscimol (an active compound found in Amanita Muscaria) is schedule 9 in Australia meaning it is illegal to forage, consume or cultivate.

Takeaway:
Psilocybe and Amanita mushrooms differ in chemistry, receptor activity, classification, and safety profile. Understanding these differences supports informed discussion and reduces risk through accurate education.

09/10/2025

Get tickets on Humanitix - Mind Medicine Australia FREE Webinar - A World-First: Transforming Mental Health Treatment with Psychedelic-Assisted Therapies hosted by Mind Medicine Australia. Online. Wednesday 29th October 2025. Find event information.

11/09/2025

What does the science really say about microdosing?

In this FREE 75-minute webinar, psychologist and author Dr. James Fadiman (USA) will provide a clear overview of:

• How microdosing may impact depression and chronic pain
• Emerging data from research studies worldwide
• Important limitations, concerns, and next steps for clinical use

This session is designed for health professionals, researchers, and anyone interested in the future of evidence-based psychedelic therapies.

📅 Wednesday, Sept 17 | 12pm AEST | Online
🎟️ Free access with registration → https://buff.ly/oUHYQEi

Address

Townsville, QLD

Alerts

Be the first to know and let us send you an email when Psychedelic Therapy NQ posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Psychedelic Therapy NQ:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram